{"name":"Berlin-Chemie AG Menarini Group","slug":"berlin-chemie-ag-menarini-group","ticker":"","exchange":"","domain":"berlinchemiemenarini.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Ibuprofen 2%","genericName":"Ibuprofen 2%","slug":"ibuprofen-2","indication":"Mild to moderate pain","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Ibuprofen 4%","genericName":"Ibuprofen 4%","slug":"ibuprofen-4","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Ibuprofen 2%","genericName":"Ibuprofen 2%","slug":"ibuprofen-2","phase":"marketed","mechanism":"Ibuprofen inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.","indications":["Mild to moderate pain","Fever reduction","Inflammatory conditions (e.g., arthritis, menstrual cramps)"],"catalyst":""},{"name":"Ibuprofen 4%","genericName":"Ibuprofen 4%","slug":"ibuprofen-4","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNTkpENkEtQlRmamNPVmVyZWJtdkd4TmYxSVRGWkRDNXZFdGRzN05TQk8xcXdNa3FMVEJ3SFZmNjB4aFh3RUh3dWJOaFNPcWNtUVVMOE1XZ01yVFJpUGhRSzA2ekdnZV80OHdDLVdSN1NLVVgxemEtZHBpTEN3NkxaQU5DUXROUEhNWGdTUllIYjV2WnQzZkxmM2xjQVlUUEhnQjRiRDZR?oc=5","date":"2026-04-05","type":"pipeline","source":"IndexBox","summary":"Oral Weight-Loss Drug Battle: Novo Nordisk vs Eli Lilly's New Treatments - News and Statistics - IndexBox","headline":"Oral Weight-Loss Drug Battle: Novo Nordisk vs Eli Lilly's New Treatments - News and Statistics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE1jOXRPLW12djBHOThQUkRXYV9NZGJKYUJGeUs3TldfdHFKN1NBZUdlOHdRemNXdXJzN0VyUm1hTzFEYmlROV9jZjZVNnpKazFHZU1xOGE2aENTSU9TSENIYk10SFF5ZW5Ea2ludTNtbXlodw?oc=5","date":"2024-07-01","type":"pipeline","source":"Adlershof - science at work","summary":"»There is quite a bit of hugging« - Adlershof - science at work","headline":"»There is quite a bit of hugging« - Adlershof","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNWlBkdnJENHZOcTJkWFJzM01TMXc4R3JqRGZDdklDU1Q0UnZtX21VeHdWWHp4eEM2ZmR6c3pSZ0lqNXpkeFV5a3hJUm5fWWw0cFZoalgyb05HeHBhY3Braks1Wkx0MFJjY3AwQUo4dWc0M096bkg3aHZEdHFxdTBUOGlRLXZLODdvcjdoaUplTk1wMnNlakRuTTFqZWV3WXRuQWpKTFBSNFM?oc=5","date":"2022-12-19","type":"pipeline","source":"politico.eu","summary":"Bitter pills: Europe and Ukraine divided over pharma sanctions - politico.eu","headline":"Bitter pills: Europe and Ukraine divided over pharma sanctions","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTFBkaFE5UHJnVXZBcHJxR0xabVVlSS1ObmJrMUFPMTBvSVd3cW1DYk4wOEd6eFdFaDFRQXVVbnJPMjBRNnJCUks4YjQzZ3dQTm11UkJUTEdPaG12dnFSLS1mWk96bUVpNF9aVW55RnNNa05tTEU?oc=5","date":"2017-11-24","type":"regulatory","source":"CHEManager","summary":"The German Capital Region - CHEManager","headline":"The German Capital Region","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxNcW5WeDY1UllFenpjVUE1NE5nRUJqb3pHMnkxTFFXeUNhOVJ5ckJ4Wl9Fdl9TS0liOGtoQ2ZIRkptblA0VlluQ2dwTkJyNTJqcG5NWDE0bG9MWHV3TnlWeEZSRHBNTEJwVGp4b2Q2NTIzdmhNSF9DNTdoQkRlZ2VUNUhFV1hZbjZKcnp0OHV4d0JiaGZqajRWOVdwaHl0Y3B5M1ZjWFBYX3Vrb25MRzZLajViWkVVT0RFRFBfQnc0eGtUODJxRGp1YV96b0dhZFdzeFlDRVhR?oc=5","date":"2016-06-07","type":"pipeline","source":"PR Newswire","summary":"Haselmeier Announces the German Launch of the BerliPen® areo 3 Through Berlin-Chemie - PR Newswire","headline":"Haselmeier Announces the German Launch of the BerliPen® areo 3 Through Berlin-Chemie","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}